Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile

Puga, Bárbara; Guerra, Carolina; Molina, Javiera; Cabrera, María Elena; Pilleux, Lilian; Calderón, Susana; Rojas, Christine; Vergara, Carmen Gloria; Rojas, Hernán; Muñoz, Lina; Lois, Vivianne; Aspillaga, Augusto; Pizarro, Álvaro.
Rev. méd. Chile ; 142(6): 707-715, jun. 2014. ilus, graf, tab
Artículo en Español | LILACS | ID: lil-722920

Documentos relacionados

  1. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.
  2. Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment.
  3. Modulation of CD19 surface expression in B cell acute lymphoblastic leukemia.
  4. Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  5. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.
  6. Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
  7. Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study.
  8. [Application of genome editing technology for the validation of pharmacogenomics in acute lymphoblastic leukemia].
  9. [Infant acute lymphoblastic leukemia: treatment strategies and new insights].
  10. Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia.